bioMérieux reported third-quarter sales of €1.04 billion, up 9.9% from €948.1 million a year earlier. Organic growth was 8.1%, ahead of analyst estimates that ranged from 3% to 7%, with a median of 5.9% in the company’s 13-analyst consensus compiled on October 21.

Demand for the company’s BioFire gastrointestinal panel increased during a Cyclospora outbreak in the United States. Sales of non-respiratory BioFire panels rose 25% year over year; bioMérieux said growth would have been about 15% without the outbreak, which it described as a one-off.

Respiratory panel sales fell 8% from a year earlier as fewer infections circulated. Over the first nine months, they were down 14%, with respiratory illness levels significantly lower than in 2025.

The company maintained its 2026 forecast for organic sales growth of 3% to 5%. The lower end assumes respiratory activity in the fourth quarter matches the same period in 2025. bioMérieux also kept its forecast for organic growth in contributive operating income before non-recurring items of 0% to 10%. It now expects a negative currency impact of about €35 million on that measure, compared with its previous estimate of €40 million to €50 million.

SPOTFIRE point-of-care platform sales reached €39 million, up 20.5% at constant exchange rates and accelerating from the 37.7% growth reported in the second quarter. Reagent sales increased 30%, and the company installed more than 900 instruments, bringing the total to nearly 8,200.

North America, which accounts for 45% of sales, grew 12.1% at constant exchange rates, supported by SPOTFIRE reagents and demand for the gastrointestinal panel. Asia Pacific sales rose 4.6%, or 8% excluding China, while lower molecular biology sales reflected regulatory changes affecting SPOTFIRE use in Japan. Europe, the Middle East and Africa grew 3.7%.

Immunoassay sales edged down 0.5%, as pressure in China and on procalcitonin reagent sales offset mid-single-digit growth across the rest of the portfolio. For the first nine months, total sales were €3.01 billion, up 2.7% organically and 0.5% as reported, including a €73 million currency impact as the euro strengthened.

Separately, the Paris Court of Appeal on October 29 upheld the dismissal of all claims against bioMérieux concerning its Lyme disease tests. A lower court had dismissed the claims in December 2021, and the appeal ruling may itself be appealed.

Sources: Investing.com News.